30th Dec 2024 09:51
(Alliance News) - Ondine Biomedical Inc on Monday said it has recruited and treated the first patient in its phase 3 clinical trial evaluating its non-antibiotic nasal photodisinfection technology.
Ondine Biomedical is a Vancouver, Canada-based life sciences company specialising in light-activated antimicrobial therapies.
The AIM-listed firm said the trial will involve approximately 5,000 patients in 14 hospitals, the first of which enrolled last Friday at Centennial Medical Center in Nashville, Tennessee.
The phase 3 trial is being conducted in collaboration with Nashville, Tennessee-based healthcare services provider HCA Healthcare Inc.
Ondine said that the group crossover study will recruit surgical patients undergoing "cardiac, orthopaedic, vascular, neurosurgical or radical mastectomy procedures" and aims to compare standard infection prevention methods to Ondine's nasal photodisinfection technology in reducing the incidence of surgical site infections.
It is anticipated that the final patient will be enrolled in mid-2025 with preliminary results expected in autumn.
Shares in Ondine rose 5.6% to 8.98 pence on Monday morning in London.
Ondine Biomedical Chief Executive Carolyn Cross said: "Our US phase 3 trial initiation is an exciting milestone towards making photodisinfection technology available to healthcare professionals who want to rapidly eliminate a broad spectrum of infection-causing pathogens without fuelling drug resistance or relying on patient compliance as is the case with topical antibiotics."
By Christopher Ward, Alliance News reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved